Recovery From Post-Stroke Aphasia With rTMS Targeting Left or Right Anterior Temporal Lobe
This project aims to tailor repetitive Transcranial Magnetic Stimulation (rTMS) target to the clinical profile of post-stroke aphasia, specifically focusing on lexicosemantic impairments, to enhance recovery. Functional Magnetic Resonance Imaging (fMRI) will provide critical insights into the effects of facilitatory ve
| Condition(s) | Stroke, Aphasia |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | This project aims to tailor repetitive Transcranial Magnetic Stimulation (rTMS) target to the clinical profile of post-stroke aphasia, specifically focusing on lexicosemantic impairments, to enhance recovery. Functional Magnetic Resonance Imaging (fMRI) will provide critical insights into the effects of facilitatory versus inhibitory stimulation on interhemispheric balance. Additionally, this study will generate new data on how lesion localization and brain connectivity influence individual responses to rTMS, explaining variability in treatment efficacy. |
| Who can participate | Inclusion Criteria: * Right-handedness (assesed using the Edinburgh Handedness Inventory) * Native English speakers * Single left hemispheric stroke * Diagnosis of aphasia and lexicosemantic impairments (e.g., anomia, semantic errors in picture naming or spontaneous speech) confirmed by a Speech and Language Pathologist or Physician Exclusion Criteria: * Severely impaired auditory comprehension (WAB Comprehension score of 0 or 1) * Major phonological impairments (defined as \> 2 errors in non-word repetition of one- and two-syllable items on the PALPA, 2) * Contraindications to rTMS (e.g., uncontrolled epilepsy, history of seizures, intracranial ferromagnetic body, cochlear implant, or factors that lower seizure threshold (see Rossi et al., 2021) * Contraindication to MRI * Stroke involvin |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | University of South Carolina |
| Locations | Columbia, South Carolina, United States |
| Start date | 2026-05-15 |
| NCT ID | NCT07608588 |
| Official listing | https://clinicaltrials.gov/study/NCT07608588 |